La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
SMS Pharmaceuticals Gestione
Gestione criteri di controllo 2/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Ramesh Potluri
Amministratore delegato
₹30.7m
Compenso totale
| Percentuale dello stipendio del CEO | 97.6% |
| Mandato del CEO | 34yrs |
| Proprietà del CEO | 36.2% |
| Durata media del management | 5.3yrs |
| Durata media del Consiglio di amministrazione | 2.1yrs |
Aggiornamenti recenti sulla gestione
SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24
Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23Recent updates
Earnings Not Telling The Story For SMS Pharmaceuticals Limited (NSE:SMSPHARMA) After Shares Rise 27%
Aug 20SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Aug 08What SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 27% Share Price Gain Is Not Telling You
Jul 04Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding Up
Feb 29SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30
Sep 11SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 28SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30
Sep 15SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30
Sep 01SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 18We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable Quality
Jun 03Should You Be Adding SMS Pharmaceuticals (NSE:SMSPHARMA) To Your Watchlist Today?
Mar 08What Type Of Shareholders Make Up SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Registry?
Feb 22The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 185% And Shareholders Are Boasting About It
Feb 08SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 18
Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Meaningful Debt Burden
Dec 09Should You Take Comfort From Insider Transactions At SMS Pharmaceuticals Limited (NSE:SMSPHARMA)?
Nov 18The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 110% And Shareholders Are Boasting About It
Oct 28What Kind Of Shareholders Hold The Majority In SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Shares?
Oct 08Are Dividend Investors Getting More Than They Bargained For With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Dividend?
Sep 17Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₹570m |
| Mar 31 2024 | n/a | n/a | ₹498m |
| Dec 31 2023 | n/a | n/a | ₹361m |
| Sep 30 2023 | n/a | n/a | ₹288m |
| Jun 30 2023 | n/a | n/a | ₹150m |
| Mar 31 2023 | ₹31m | ₹30m | -₹71m |
| Dec 31 2022 | n/a | n/a | -₹42m |
| Sep 30 2022 | n/a | n/a | ₹9m |
| Jun 30 2022 | n/a | n/a | ₹259m |
| Mar 31 2022 | ₹38m | ₹26m | ₹622m |
| Dec 31 2021 | n/a | n/a | ₹789m |
| Sep 30 2021 | n/a | n/a | ₹911m |
| Jun 30 2021 | n/a | n/a | ₹791m |
| Mar 31 2021 | ₹47m | ₹21m | ₹625m |
| Dec 31 2020 | n/a | n/a | ₹458m |
| Sep 30 2020 | n/a | n/a | ₹319m |
| Jun 30 2020 | n/a | n/a | ₹308m |
| Mar 31 2020 | ₹26m | ₹20m | ₹316m |
| Dec 31 2019 | n/a | n/a | ₹386m |
| Sep 30 2019 | n/a | n/a | ₹405m |
| Jun 30 2019 | n/a | n/a | ₹406m |
| Mar 31 2019 | ₹32m | ₹20m | ₹400m |
| Mar 31 2018 | ₹32m | ₹20m | ₹317m |
Compensazione vs Mercato: La retribuzione totale di Ramesh ($USD 366.60K ) è superiore alla media delle aziende di dimensioni simili nel mercato Indian ($USD 246.97K ).
Compensazione vs guadagni: La retribuzione di Ramesh è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Ramesh Potluri (66 yo)
34yrs
Mandato
₹30,745,000
Compensazione
Mr. Ramesh Babu Potluri has been the Chairman and Managing Director of SMS Pharmaceuticals Limited since August 30, 1990. Mr. Potluri has pioneered the vision of developing SMS in to one of the leading Pha...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman & MD | 34yrs | ₹30.75m | 36.22% ₹ 9.2b | |
| Chief Financial Officer | 6.9yrs | ₹2.30m | Nessun dato | |
| Company Secretary & Compliance Officer | 2.5yrs | ₹1.49m | Nessun dato | |
| Executive Director | 3.6yrs | ₹6.69m | 15.74% ₹ 4.0b | |
| Assistant General Manager of HR and Legal | no data | Nessun dato | Nessun dato | |
| Head of HRD and General Manager of Purchases | no data | Nessun dato | Nessun dato |
5.3yrs
Durata media
61yo
Età media
Gestione esperta: Il team dirigenziale di SMSPHARMA è esperto e expertise (durata media dell'incarico 5.3 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman & MD | 34yrs | ₹30.75m | 36.22% ₹ 9.2b | |
| Executive Director | 4.2yrs | ₹6.69m | 15.74% ₹ 4.0b | |
| Additional Non-Executive Non-Independent Director | no data | Nessun dato | 2.58% ₹ 659.8m | |
| Non-Executive & Independent Director | 5yrs | ₹100.00k | Nessun dato | |
| Non-Executive & Independent Director | 6.3yrs | ₹330.00k | 0.035% ₹ 9.0m | |
| Additional Non-Executive Independent Director | no data | Nessun dato | Nessun dato | |
| Non-Executive Non-Independent Director | no data | Nessun dato | Nessun dato | |
| Non-Executive Independent Director | no data | Nessun dato | Nessun dato |
2.1yrs
Durata media
54yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di SMSPHARMA non è considerato esperto (durata media del mandato 2.1 anni), il che suggerisce un nuovo consiglio.